Hillstream BioPharma is a pre-clinical biotechnology company developing therapeutic candidates targeting ferroptosis for treatment-resistant cancers. It develops immune-oncology therapeutics such as HSB-1216, an IMCD (iron-mediated cell death) inducer, targeting a variety of solid tumors. The company also develops and uses Quatramer, a proprietary tumor targeting platform, and TridentAI, an artificial intelligence precision medicine platform for the identification of biomarkers in its clinical programs.